REG - Tissue Regenix Group - Distribution agreement - OrthoPure® XT in Germany

Tissue RegenixAnnouncement

22/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221122:nRSV1322Ha&default-theme=true

RNS Number : 1322H  Tissue Regenix Group PLC  22 November 2022

Tissue Regenix Group plc

('Tissue Regenix', the 'Company' or 'the Group')

 

Distribution agreement for OrthoPure® XT in Germany

Second European distribution agreement signed in 2022 as part of the European
growth strategy

 

Tissue Regenix Group (AIM: TRX), the regenerative medical devices company,
announces that it has signed an exclusive distribution agreement with 2med
GmbH ('2med'), a Hamburg-based service provider for surgical and
orthobiological treatments of the musculoskeletal system, for the distribution
of OrthoPure® XT in Germany.

 

The multiyear distribution agreement currently covers Germany. However, it
also has the potential for extension into additional territories covered by
2med representatives. 2med is an independent specialist dealer of surgical and
biological therapy procedures for shoulder, knee, foot and ankle, with a focus
on treatments that support an active and independent lifestyle.

 

The OrthoPure® XT decellularised xenograft ligament utilises Tissue Regenix's
patented dCell® technology and is the only available non-human biologic graft
indicated for certain ligament reconstruction procedures. The CE-marked
OrthoPure® XT can be used for revision of anterior cruciate ligament (ACL)
reconstruction procedures and reconstruction of other knee ligaments,
including multi-ligament and primary procedures when the autograft is not an
option.

 

Thomas Guenther, Commercial Director at 2med, commented: "2med are delighted
to be representing OrthoPure®  XT in Germany. The initial feedback from our
knee surgeons is very positive and we are excited to offer this new, easy to
use option for German patients with damaged ACL and other knee ligaments."

Daniel Lee, Chief Executive Officer of Tissue Regenix Group, commented:
"Following the success of our partnership with Geistlich Biomaterials Italia,
that we announced in March 2022, we are pleased to have signed this
distribution agreement with 2med for Germany. 2med's work with doctors and
patients, to offer advanced treatments and minimise rehabilitation times, are
aligned with this innovative product and has made 2med one of the leading
specialist dealers in Germany. We look forward to working with 2med and
continuing to expand the use of OrthoPure® XT across Europe."

 

For more information:

 

 Tissue Regenix Group plc              www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer  Via Walbrook PR

 Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)          Tel: +44(0)20 7710 7600
 Ben Maddison / Nick Harland / Kate Hanshaw

 Walbrook PR Ltd                                                        Tel: +44(0)20 7933 8780
 Alice Woodings / Lianne Applegarth                                     TissueRegenix@walbrookpr.com

 

 

About Tissue Regenix (www.tissueregenix.com)

Tissue Regenix is a leading medical device company in the field of
regenerative medicine. The company's patented decellularisation ('dCELL®')
technology removes DNA and other cellular material from animal and human soft
tissue, leaving an acellular tissue scaffold, which is not rejected by the
patient's body and can then be used to repair diseased or damaged body
structures. Current applications address many critical clinical needs in
sports medicine, foot and ankle and wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech
company that specialises in regenerative medicine and is dedicated to the
development of innovative osteoinductive and wound care scaffolds that enhance
healing opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general orthopaedic, dental
and ophthalmological surgical procedures.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAEFFALEAFAA